Meta-analysis of dermatological toxicities associated with sorafenib

Clinical and Experimental Dermatology

Volumn 36, Issue 4, 2011, Pages 344-350

  Zhang, L ^a   Zhou, Q ^b   Ma, L ^a   Wu, Z ^b   Wang, Y ^a  

^a Department of Oncology ^*  (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB;

ALOPECIA; DESQUAMATION; DISEASE SEVERITY; DRUG EFFECT; DRY SKIN; HAND FOOT SKIN REACTION; HUMAN; INCIDENCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; RISK ASSESSMENT; RISK FACTOR; SKIN TOXICITY; SOLID TUMOR; SYSTEMATIC REVIEW;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; SKIN DISEASES;

EID: 79955960147     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2011.04060.x     Document Type: Review

References (36)

1. Wilhelm SM, Carter C, Tang L et al. BAY43-9006 exhibits broad spectrum oral antitumour activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumour progression and angiogenesis. Cancer Res 2004; 64: 7099-109.
2. US Food and Drug Administration. Nexavar (sorafenib) prescribing information. Available at: (accessed 10 June 2010).
3. Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505-12.
4. Escudier B, Eisen T, Stadler WM et al. Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27: 3312-18.
5. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
6. Eisen T, Ahmad T, Flaherty KT et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer 2006; 95: 581-6.
7. Dreicer R, Li H, Stein M et al. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer 2009; 115: 4090-5.
8. Bianchi G, Loibl S, Zamagni C et al. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs 2009; 20: 616-24.
9. Aragon-Ching JB, Jain L, Gulley JL et al. Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int 2009; 103: 1636-40.
10. Gupta-Abramson V, Troxel AB, Nellore A et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008; 26: 4714-19.
11. Elser C, Siu LL, Winquist E et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 2007; 25: 3766-73.
12. Schiller JH, Lee JW, Hanna NH et al. A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens. J Clin Oncol 2008; 26 (Suppl.): 8014 (abstract).
13. Wiebe L, Kasza K, Maki RG et al. Sorafenib (SOR) is active in patients with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): a phase ll trial of the University of Chicago Phase ll Consortium. J Clin Oncol 2008; 26 (Suppl.): 10502 (abstract).
14. Gatzemeier U, Blumenschein G, Fosella F et al. Phase II trial of single agent sorafenib in patients with advanced non-small cell lung carcinoma. J Clin Oncol 2008; 26 (Suppl.): 7002 (abstract).
15. Escudier B, Szczylik C, Hutson TE et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 1280-9.
16. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
17. Di Lorenzo G, Cartenì G, Autorino R et al. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol 2009; 27: 4469-74.
18. Maki RG, D'Adamo DR, Keohan ML et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009; 27: 3133-40.
19. Yau T, Chan P, Ng KK et al. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer 2009; 115: 428-36.
20. Moreno-Aspitia A, Morton RF, Hillman DW et al. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J Clin Oncol 2009; 27: 11-15.
21. Dahut WL, Scripture C, Posadas E et al. A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 2008; 14: 209-14.
22. Akaza H, Tsukamoto T, Murai M et al. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 2007; 37: 755-62.
23. Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293-300.
24. Knox JJ, Figlin R, Stadler WM et al. The advanced renal cell carcinoma sorafenib (ARCCS) expanded access trial in North America: safety and efficacy. J Clin Oncol 2007; 25 (Suppl. 18): 5011 (abstract).
25. D'Adamo DR, Keohan M, Schuetze S et al. Clinical results of a phase II study of sorafenib in patients (pts) with non-GIST sarcomas (CTEP study #7060). J Clin Oncol 2007; 25 (Suppl. 18): 10001 (abstract).
26. Hobday TJ, Holen K, Picus J et al. MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumours (NET): a Phase II consortium (P2C) study. J Clin Oncol 2007; 25 (Suppl. 18): 4004 (abstract).
27. Porta C, Paglino C, Imarisio I et al. Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med 2007; 7: 127-34.
28. Nagore E, Insa A, Sanmartin O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia (hand-foot) syndrome: incidence, recognition and management. Am J Clin Dermatol 2000; 1: 225-34.
29. Robert C, Mateus C, Spatz A et al. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol 2009; 60: 299-305.
30. Lai SKT, Lacouture M. Hand-foot and stump syndrome to sorafenib. J Clin Oncol 2007; 25: 341.
31. Lacouture ME, Reilly LM, Gerami P et al. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 2008; 19: 1955-61.
32. Tsai KY, Yang CH, Kuo TT et al. Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma. J Clin Oncol 2006; 24: 5786-8.
33. Morita E, Lee DG, Sugiyama M et al. Expression of c-kit ligand in human keratinocytes. Arch Dermatol Res 1994; 286: 273-7.
34. Robert C, Soria JC, Spatz A et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005; 6: 491-500.
35. Lee WJ, Lee JL, Chang SE et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 2009; 161: 1045-51.
36. Wood LS. Management of vascular endothelial growth factor and multikinase inhibitor side effects. Clin J Oncol Nurs 2009; 13 (Suppl.): 13-18.